Amgen - International Biopharmaceutical Industry

news

Mirati matches Amgen with updated data for KRAS-blocking cancer drug

Mirati Therapeutics hopes to later this year win U.S. approval of only the second drug able to target tumors spurred by mutations in an elusive gene called KRAS. Upd...

30 May 2022 news Amgen | cancer

Continue Reading →

news

FDA sets back Novartis’ best chance at a COVID-19 drug

Dive Brief: Novartis is reevaluating its commitment to an experimental COVID-19 treatment originally developed by fellow Swiss drug company Molecular Partners afte...

28 April 2022 news Amgen | COVID-19

Continue Reading →

news

Lilly deepens research ties in China with biotech deal

Lilly's deal with Regor is another example of large pharmaceutical companies in the U.S. and Europe showing interest in Chinese biotechs for their research, rather th...

13 December 2021 news Amgen | Chinese biotech

Continue Reading →

news

Biohaven to seek FDA approval for second migraine drug after study success

While a smaller biotech company, Biohaven has succeeded in a market led by large pharmaceutical firms like Lilly, AbbVie and, in the preventive treatment setting, Amg...

10 December 2021 news ABBVIE | Amgen

Continue Reading →

news

Biohaven’s pipeline takes a hit as drug for rare neurological disease falls short in trial

Biohaven has built itself into a nearly $10 billion company on the strength of its migraine drug Nurtec, which surprised Wall Street with second-quarter sales that we...

30 September 2021 news ABBVIE | Amgen

Continue Reading →

news

In a first, FDA approves an ‘interchangeable’ biosimilar for diabetes

The promise of biosimilars — that competition would bring down the prices of complex biological drugs — hasn't materialized in the U.S. in the way many expected. Comp...

5 August 2021 news ABBVIE | Amgen

Continue Reading →

news

Amgen, expecting higher demand for its medicines, to build plant in North Carolina

Facing increased competition for many of its top-selling drugs, Amgen is focusing on building its pipeline of drugs for the future, especially in the areas of oncolog...

5 August 2021 news Amgen | cancer drug

Continue Reading →

news

Amgen, Novartis’ closely watched migraine drug approved

Amgen and Novartis on Thursday secured Food and Drug Administration approval for Aimovig, the first regulatory thumbs up for a new class of migraine treatments ca...

21 May 2018 news Amgen | approved

Continue Reading →